Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0006632003
Mon, 05.02.2024       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, February 5, 2024     Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab M [ … ]
Technical analysis Trade The News (TTN)
To the publication
Tue, 30.01.2024       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, January 30, 2024   Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability Preliminary 2023 Monjuvi U.S. net pro [ … ]
Technical analysis Trade The News (TTN)
To the publication
Thu, 14.12.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, December 14, 2023   Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) resolved to increase [ … ]
Technical analysis Trade The News (TTN)
To the publication
Wed, 13.12.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, December 13, 2023   Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) announces that its Management Board, with the [ … ]
Technical analysis Trade The News (TTN)
To the publication
Mon, 20.11.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, November 20, 2023 Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction MANIFEST-2 [ … ]
Technical analysis Trade The News (TTN)
To the publication
Wed, 25.10.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, October 25, 2023     Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023   Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 [ … ]
Technical analysis Trade The News (TTN)
To the publication
Thu, 02.03.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, March 2, 2023   Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) today announces  [ … ]
Technical analysis Trade The News (TTN)
To the publication
Thu, 02.03.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, March 2, 2023   Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) today announces  [ … ]
Technical analysis Trade The News (TTN)
To the publication
Thu, 05.01.2023       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, January 5, 2023   Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability   Preliminary 2022 Monjuvi U.S. net product sales of U [ … ]
Technical analysis Trade The News (TTN)
To the publication
Mon, 14.11.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, November 14, 2022   Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease  GRADUATE studies did not meet primary endpoint MorphoSys  [ … ]
Technical analysis Trade The News (TTN)
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 03.07.2024, Calendar Week 27, 185th day of the year, 181 days remaining until EoY.